Drug Profile
Research programme: peptide therapeutics - Allostera Pharma
Alternative Names: APG 101.10; APG 2305Latest Information Update: 30 Mar 2011
Price :
$50
*
At a glance
- Originator Allostera Pharma
- Class Peptides; Small molecules
- Mechanism of Action Insulin-like growth factor-I receptor antagonists; Interleukin 1 receptor antagonists; Interleukin 13 receptor antagonists; Interleukin 18 inhibitors; Interleukin 23 inhibitors; Interleukin 4 receptor antagonists; Tumour necrosis factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration; Asthma; Cancer; Chronic obstructive pulmonary disease; Emphysema; Gout; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Type 2 diabetes mellitus
Most Recent Events
- 08 Jul 2009 Early research in Age-related macular degeneration in Canada (PO)
- 08 Jul 2009 Early research in Asthma in Canada (PO)
- 08 Jul 2009 Early research in Chronic obstructive pulmonary disease in Canada (PO)